ISSAR pharma licenses its NCEs based on peptide technology in hopes of potential collaborations :
ISSAR has been on the lookout for partnering with other companies to get assistance in designing novel peptide–based drugs. It believes that collaborations would allow it to make affordable and accessible drugs for various unmet healthcare needs. In line with this view, the company has decided to license its NCEs[1] based on peptide technology.
With over 25 years of experience in R&D[2], ISSAR pharma has lined up several life–changing peptide molecules to date. The firm uses solid–phase synthesis technology for synthesizing custom peptides. It also synthesizes API[3] peptides and cosmetic peptides.
ISSAR’s development pipeline has shown that the company has targeted certain therapeutic areas. These include oncology, dermatology, gastroenterology, and diseases of the bones and joints. This was the first Indian company to conduct phase – 1 clinical trial for launching an indigenous peptide drug called Melagin. This drug was launched in 2004 and is used for treating vitiligo.
The company has around 2 commercialized products in the market. It also holds approximately 7 patents and over 6 commercially viable products under development. The company’s FDA[4] – compliant manufacturing facility is in Genome Valley, Hyderabad. This facility is explicitly involved in working with peptides. Read about What is the role of USFDA in protecting health?
Melagin, a peptide molecule of ISSAR has now been introduced as Novoskin in the market. It has improved properties and effectiveness.
The second NCE of ISSAR is Xylentra. This is used for treating burns and microbial infections. It has recently been licensed to Viatris that was formerly known as Mylan Laboratories. This company has also developed molecules that treat prevalent conditions in the Western world. These include conditions like Inflammatory Bowel Disease, Psoriasis, and Sepsis.
Abbreviation :
- 1. New Chemical Entities
- 2. Research and Development
- 3. Active Pharmaceutical Ingredient
- 4. Food and Drug Administration